Nymban1.gif (20124 bytes)

  Inside NymbleInvestor.com

  redcheck.gif (879 bytes) 

The NymbleInvestor.com Research Team opens up shop at BiotechMonthly.com.   more...     new site...

  redcheck.gif (879 bytes) 

Looking for research on biotechnology stocks like Genta (GNTA), Alliance Pharmaceuticals (ALLP), and Dendreon (DNDN)?. How about Id Biomedical (IDBE), Seattle Genetics (SGEN), and Esperion (ESPR)  more...

  redcheck.gif (879 bytes) 

Are you looking for independent research? Or perhaps an independent researcher to interview for a perspective not skewed by investment bankers? Come learn more about us at our new site: BiotechMonthly.com
      
NymbleInvestor
Prospect List Return
Inception to Close
+44.43%
NASDAQ

- 34.04%

Dow Indu - 15.87%
S&P-500 - 20.06%
Russell 2K - 4.88%

Measured from date of our web site's debut 5/13/99 through our last Daily Report on 10/15/01.


Performance Details

Past returns may not be a good indicator of future performance. See our Terms and Conditions for more details.

 

       
  Inside NymbleInvestor.com
We've got a new site! The NymbleInvestor Research Team that gave our Subscribers the performance listed at the top of this page has a new home:

Click to visit our new site

Our new web site, BiotechMonthly.com, helps investors understand the ins and outs of investing in development-stage biotechnology companies. The monthly NIBM Newsletter focuses on one company or sub-sector. We explain the science in terms anyone can understand at a level of detail that will satisfy experienced biotech investors. We supplement the Newsletter with the mid-month NIBM Update and special NIBM Alerts we send out via e-mail whenever breaking news affects a stock we cover.

We invite you to visit our new site and with the same research team that clobbered the major market averages over the most volatile 29 months in market history. Join the biotech executives, investment bank analysts, fund managers, financial advisors, individual investors, and members of the media who read our publications.

Follow along as we continue our tradition of beating the performance of the major market averages.

Please visit us at BiotechMonthly.com. If you have an interest in biotechnology, it will be worth your while.


An American Tragedy

Like most in the financial community, we experienced an enormous sense of loss when the barbarians attacked the WTC complex and the Pentagon. Colleagues and friends at firms such as Cantor Fitzgerald perished in the destruction.

On Tuesday morning, we pulled down our normal home page and substituted it with a short note and contact information for the Red Cross to assist those interested in donating blood or money.

As the week wore on, we supplemented the special page with updates on the market. We saved the page at the request of our Subscribers; you can access it here.


An American Tragedy Revisited

The staff at NymbleInvestor.com would like to encourage you to remember those who need help in your local community. America poured out its heart and opened up its wallet to the victims of the disaster in New York, Pennsylvania, and Washington, D.C. We are to be commended.

However, donations have dried up to service organizations and charities right in our own backyards. Right here in Seattle, and in cities across the nation, charities are having to lay off people and shutter their doors because people are directing all their charitable contributions elsewhere.

This holiday season we ask all our readers to make sure and help out those close to where you live. Make sure or give money, your time, or both to a local charity.

A new technology partner

BlueSky Broadband  has pioneered technology creating ubiquitous broadband access across all networks, even among those previously unknown to each other. Their patent-pending technology enables the uniform, consistent user experience sought by end-users and network providers alike. Check out one of the hottest startups in the Wi-Fi/public broadband network space.

Click here to visit BlueSky Broadband.


Entire site and contents © 1999-2003 Nymble Investments. All rights reserved.

For the use of authorized users according to
the Terms and Conditions. Unauthorized distribution of these pages
or their contents is a violation of state and federal copyright law.